Literature DB >> 25192825

Identification of swine influenza virus epitopes and analysis of multiple specificities expressed by cytotoxic T cell subsets.

Lasse E Pedersen1, Solvej Ø Breum, Ulla Riber, Lars E Larsen, Gregers Jungersen.   

Abstract

BACKGROUND: Major histocompatibility complex (MHC) class I peptide binding and presentation are essential for antigen-specific activation of cytotoxic T lymphocytes (CTLs) and swine MHC class I molecules, also termed swine leukocyte antigens (SLA), thus play a crucial role in the process that leads to elimination of viruses such as swine influenza virus (SwIV). This study describes the identification of SLA-presented peptide epitopes that are targets for a swine CTL response, and further analyses multiple specificities expressed by SwIV activated CTL subsets.
FINDINGS: Four SwIV derived peptides were identified as T cell epitopes using fluorescent influenza:SLA tetramers. In addition, multiple CTL specificities were analyzed using peptide sequence substitutions in two of the four epitope candidates analyzed. Interestingly both conserved and substituted peptides were found to stain the CD4-CD8+ T cell subsets indicating multiple specificities.
CONCLUSIONS: This study describes a timely and cost-effective approach for viral epitope identification in livestock animals. Analysis of T cell subsets showed multiple specificities suggesting SLA-bound epitope recognition of different conformations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25192825      PMCID: PMC4161877          DOI: 10.1186/1743-422X-11-163

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


Background

During the last two centuries influenza virus has constantly challenged animal and human health by seasonal outbreaks, most recently illustrated in the emerging 2009 pandemic H1N1 virus which, according to the World Health Organization (WHO), lead to more than 18.000 human deaths. Swine influenza virus (SwIV) is a common pathogen involved in the porcine respiratory disease complex. Beyond the veterinary implications, influenza infections in pigs also imply an important public health risk due to potential inter-species transmission of new reassortant strains of influenza viruses with pandemic capacity [1-4]. Human influenza virus vaccines are regularly updated with contemporary strains in contrast to commercially SwIV vaccines leading to inadequate protection against antigenic diverse viruses. In order to address new vaccine approaches which, based on common T cell epitopes, are able to provide a broader protection against a range of antigenic different viral strains, it is necessary to identify the peptide epitopes that are targets for a swine cytotoxic T cell response. The selective binding and presentation of peptides in MHC complexes play a crucial role in the adaptive immune response to infectious diseases and vaccines [5, 6]. Such peptide:MHC (pMHC) complexes are scanned by circulating CD4-CD8+ cytotoxic T cells (CTLs) of the host immune system, occasionally leading to immune activation if the peptide is of foreign origin representing a potential danger to the host. To date pMHC tetramers have been described in work related to the analysis of mice [7], human [8, 9], bovine [10], and porcine [11] immune responses. In pigs, MHC class I molecules are termed swine leukocyte antigens (SLA) and one of the most commonly occurring SLA alleles, the SLA-1*0401 [12], has recently been mapped for its peptide binding preferences [13]. This study illustrates the use of pSLA fluorescent tetramers to identify SwIV derived epitopes. In summary, porcine fluorescent tetramers were generated with carefully selected influenza virus peptide ligands to measure immune responses against swine influenza virus after immunization of SLA class I matched pigs with inactivated virus.

Methods

A total of 20 pigs were used in this study of which 16 expressed the SLA-1*0401 class I molecule. All procedures of animal handling and experimentation were approved by the Danish Animal Experiments Inspectorate. Experimental animals received chemically (C3H4O2) inactivated swine influenza A virus of different strains given in equal volumes of Freund’s Incomplete adjuvant with 4 repeated immunizations at three-week intervals (Table 1). Initially, blood samples were collected from all pigs followed by SLA allele typing using PCR-SSP [14-16]. Candidate SwIV epitopes were selected using in silico predictions for binding by the online available NetMHCpan algorithm [17-19], and combined with previously mapped preferences expressed by SLA-1*0401 [13]. Chosen candidate epitopes were then tested for SLA-1*0401 binding affinity using a previously described immunosorbent assay [20]. pSLA-1*0401 based fluorescent tetramers were produced as described previously [9], and porcine CD8+ cytotoxic T cell labeling was analyzed by flow cytometry. APC- and BV421-fluorochromes were used for labeling tetramers whereas PE-conjugated mAb against porcine CD8α (clone 76-2-11, BD Pharmingen) and FITC-conjugated mAb against porcine CD4 (clone 74-12-4, BD Pharmingen) were used for additional cell surface staining.
Table 1

Influenza peptide epitopes and immunization strains

SLA tetramer peptide epitopesImmunization strains 1-5
12345
SwIV candidate epitopeViral protein of originAA position* in virusNucleotide position* in virusA/swine/Den mark/101310- 1/2011(H1N1pdm09)A/swine/Denmark/101568-1/2011(H1pdmN2†)A/swine/Denmark/19126/1993 (H1N1)A/swine/Denmark/101490-3/2011(H1N1)A/swine/Denmark/1037-2/2011(H1N2†)
CTELKLSDYNP44-52130-156++CTELQLSDYCTELQLSDYCTELQLSDY
GTEKLTITYPB2623-5311567-1593+++++
SSSFSFGGFPB2320-328958-984+++++
YVFVGTSRYHA215-223643-669++YVSVESSKYYVSVVSSKYYVSVVSSKY

Comparison of influenza virus candidate epitope sequences within the different viral strains used for immunizations. (+) SwIV candidate epitope sequence is 100% conserved in the viral strain used for immunization. (*) Amino acid position relative to start codon in virus A/swine/Denmark/12687/2003, (†) reassortant swine influenza virus encoding a human-like N2 gene [21]. Amino acids in bold mark substitutions in the sequence within the immunization strain compared to the respective candidate epitopes used for tetramer analysis.

Influenza peptide epitopes and immunization strains Comparison of influenza virus candidate epitope sequences within the different viral strains used for immunizations. (+) SwIV candidate epitope sequence is 100% conserved in the viral strain used for immunization. (*) Amino acid position relative to start codon in virus A/swine/Denmark/12687/2003, (†) reassortant swine influenza virus encoding a human-like N2 gene [21]. Amino acids in bold mark substitutions in the sequence within the immunization strain compared to the respective candidate epitopes used for tetramer analysis.

Results

Virally derived T cell epitopes in swine were identified by ex vivo analysis of candidate epitope peptides, based on in silico predictions and in vitro validation. Four influenza virus derived candidate epitope peptides (CTELKLSDY, GTEKLTITY, SSSFSFGGF, YVFVGTSRY) and one synthetically designed reference peptide (ASYGAGAGY) were selected for analysis based on a prediction to be bound by the SLA-1*0401 molecule. All selected peptides had NetMHCpan prediction rank scores of 1.00 or lower meaning that the peptide had a predicted affinity within the 1 percentile best candidates compared to a pool of 1,000.000 natural peptides (Table 2) [17-19]. Following in vitro testing it was found that all four influenza virus peptides were bound with high affinity by the SLA-1*0401 MHC class I molecule, and identified as T cell epitopes by ex vivo flow cytometry analysis using influenza:SLA tetramers. Positive samples were defined by a minimum threshold of 2-fold higher staining percentage compared to the negative background control, as previously set by others [22]. Six of the 16 SLA-matched pigs were found to express activated CTL populations showing specificities against the SwIV peptides post immunization (Table 3). SwIV tetramer staining above the 2-fold threshold ranged between 0.8 and 5.3% of the total CD4-CD8αhigh cell population depending on the different epitopes and animals (Table 3, bold numbers). A specific T cell subset of 6.5% of the CD4-CD8αhigh population stained positive for the GTEKLTITY epitope as compared to the negative background control of 1.2% (Figure 1). In addition, substitutions were introduced in 50% of the epitope candidates to examine individual T cell subsets in regard to the expression of multiple T cell receptor (TCR) specificities. Interestingly both conserved and substituted epitope candidates were found to stain the CD4-CD8αhigh T cell subsets. Staining percentages of epitopes including amino acid substitutions compared to their respective immunization strain are marked by an asterix (Table 3).
Table 2

Peptide predictions and affinities

Peptide sequence NetMHCpanprediction rankSLA-1*0401 affinity K D(nM)
CTELKLSDY 1.0016
GTEKLTITY 0.8034
SSSFSFGGF 0.80378
YVFVGTSRY 0.10325
ASYGAGAGY 0.0519

Peptide sequences selected for affinity analysis based on NetMHCpan prediction ranks and SLA-1*0401 amino acid requirements for binding. The lower the KD value the higher the affinity for binding. Peptides having KD values <500 nM are considered as intermediate affinity ligands whereas a KD value <100 nM represents a high affinity binding peptide ligand.

Table 3

Influenza virus tetramer staining

Animal ID/SwIV strainTetramer SwIV peptidePeptide substituted from immunization strainFrequency of tetramer (APC + BV421+) cells
(Tetramer + cells subtracted negative control)
ASYGAGAGYNegative control0.80 (0.00)
1/ CTELKLSDYNo1.70 (0.90)
1 GTEKLTITYNo1.90 (1.10)
SSSFSFGGFNo1.70 (0.90)
YVFVGTSRYNo1.60 (0.80)
ASYGAGAGYNegative control0.60 (0.00)
2/ CTELKLSDYNo1.70 (1.10)
3 GTEKLTITYNo1.50 (0.90)
SSSFSFGGFNo1.40 (0.80)
YVFVGTSRYNo1.50 (0.90)
ASYGAGAGYNegative control1.20 (0.00)
CTELKLSDYNo6.30 (5.10)
4/ GTEKLTITYNo6.50 (5.30)
3 SSSFSFGGFNo3.90 (2.70)
YVFVGTSRYNo5.80 (4.60)
ASYGAGAGYNegative control2.60 (0.00)
CTELKLSDYYes5.80 (3.20*)
6/ GTEKLTITYNo5.80 (3.20)
3 SSSFSFGGFNo4.90 (2.30)
YVFVGTSRYYes5.90 (3.30*)
ASYGAGAGYNegative control0.90 (0.00)
CTELKLSDYYes3.00 (2.10*)
8/ GTEKLTITYNo2.40 (1.50)
4 SSSFSFGGFNo1.90 (1.00)
YVFVGTSRYYes2.70 (1.80*)
ASYGAGAGYNegative control1.10 (0.00)
CTELKLSDYYes2.80 (1.70*)
16/ GTEKLTITYNo2.50 (1.40)
5 SSSFSFGGFNo2.30 (1.20)
YVFVGTSRYYes2.70 (1.60*)

Tetramer staining frequencies. Percentile numbers in bold show specific tetramer staining post background subtraction. The relative background staining has been defined for each animal by a negative control tetramer (ASYGAGAGY). Italic percentile numbers indicate non-specific staining. Percentages marked by an asterix (*) indentify positive staining by influenza peptides which are sequence substituted compared to the respective immunization strains.

Figure 1

Influenza virus tetramer staining of porcine CD4 CD8 α T cells. SwIV tetramer staining of CD4-CD8αhigh T cell subsets. Individual samples were stained by an epitope candidate tetramer (GTEKLTITY) and a negative control tetramer (ASYGAGAGY). Singlet lymphocytes are gated in P1 (blue). CD4-CD8αhigh cells are gated in P2 (orange), and CD4-CD8αhigh APC+BV+ tetramer double positive cells are shown in P3 (green) for animal number 4. Percentages of tetramer reactive cells within the CD4-CD8αhigh population are shown for each sample.

Peptide predictions and affinities Peptide sequences selected for affinity analysis based on NetMHCpan prediction ranks and SLA-1*0401 amino acid requirements for binding. The lower the KD value the higher the affinity for binding. Peptides having KD values <500 nM are considered as intermediate affinity ligands whereas a KD value <100 nM represents a high affinity binding peptide ligand. Influenza virus tetramer staining Tetramer staining frequencies. Percentile numbers in bold show specific tetramer staining post background subtraction. The relative background staining has been defined for each animal by a negative control tetramer (ASYGAGAGY). Italic percentile numbers indicate non-specific staining. Percentages marked by an asterix (*) indentify positive staining by influenza peptides which are sequence substituted compared to the respective immunization strains. Influenza virus tetramer staining of porcine CD4 CD8 α T cells. SwIV tetramer staining of CD4-CD8αhigh T cell subsets. Individual samples were stained by an epitope candidate tetramer (GTEKLTITY) and a negative control tetramer (ASYGAGAGY). Singlet lymphocytes are gated in P1 (blue). CD4-CD8αhigh cells are gated in P2 (orange), and CD4-CD8αhigh APC+BV+ tetramer double positive cells are shown in P3 (green) for animal number 4. Percentages of tetramer reactive cells within the CD4-CD8αhigh population are shown for each sample.

Discussion and conclusion

This study describes a timely and cost-effective approach for viral epitope analysis and identification in livestock animals. In addition, we hypothesized CD8+ cytotoxic T cell subsets to possess multiple specificities. Interestingly, it was found that conserved as well as substituted epitopes positively stained T cell subsets suggesting SLA-bound epitope recognition of different conformations. These findings correlate with previous studies showing that CTL subsets expressing individual TCRs are capable of recognizing ligands of various conformations presented by the same MHC [23, 24]. In conclusion, the data and approaches described have great potential for future studies using the pig as a large animal model for viral epitope identification. Furthermore, by including sequence substituted MHC ligands in the analysis it was illustrated how CD4-CD8+ T cell subsets were capable of expressing multiple T cell receptor ligand specificities. Finally, identification of T cell epitopes conserved across all types, subtypes and strains of influenza viruses, and including mutations, can be valuable knowledge in terms of future vaccine design as well as in achieving a better understanding of the immune responses elicited by vaccination and natural infection.
  24 in total

1.  Characterization of swine leukocyte antigen polymorphism by sequence-based and PCR-SSP methods in Meishan pigs.

Authors:  Chak-Sum Ho; Erin S Rochelle; Gregory W Martens; Lawrence B Schook; Douglas M Smith
Journal:  Immunogenetics       Date:  2006-10-13       Impact factor: 2.846

Review 2.  Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism.

Authors:  Brian M Baker; Daniel R Scott; Sydney J Blevins; William F Hawse
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

3.  Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction.

Authors:  C Sylvester-Hvid; N Kristensen; T Blicher; H Ferré; S L Lauemøller; X A Wolf; K Lamberth; M H Nissen; L Ø Pedersen; S Buus
Journal:  Tissue Antigens       Date:  2002-04

4.  NetMHCpan, a method for MHC class I binding prediction beyond humans.

Authors:  Ilka Hoof; Bjoern Peters; John Sidney; Lasse Eggers Pedersen; Alessandro Sette; Ole Lund; Søren Buus; Morten Nielsen
Journal:  Immunogenetics       Date:  2008-11-12       Impact factor: 2.846

Review 5.  Gene map of the extended human MHC.

Authors:  Roger Horton; Laurens Wilming; Vikki Rand; Ruth C Lovering; Elspeth A Bruford; Varsha K Khodiyar; Michael J Lush; Sue Povey; C Conover Talbot; Mathew W Wright; Hester M Wain; John Trowsdale; Andreas Ziegler; Stephan Beck
Journal:  Nat Rev Genet       Date:  2004-12       Impact factor: 53.242

6.  Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse.

Authors:  C D Lemke; J B Graham; D M Lubaroff; A K Salem
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-01-25       Impact factor: 5.554

7.  Porcine major histocompatibility complex (MHC) class I molecules and analysis of their peptide-binding specificities.

Authors:  Lasse Eggers Pedersen; Mikkel Harndahl; Michael Rasmussen; Kasper Lamberth; William T Golde; Ole Lund; Morten Nielsen; Soren Buus
Journal:  Immunogenetics       Date:  2011-07-08       Impact factor: 2.846

8.  Influenza a virus with a human-like n2 gene is circulating in pigs.

Authors:  Solvej Østergaard Breum; Charlotte Kristiane Hjulsager; Ramona Trebbien; Lars Erik Larsen
Journal:  Genome Announc       Date:  2013-09-19

9.  One-pot, mix-and-read peptide-MHC tetramers.

Authors:  Christian Leisner; Nina Loeth; Kasper Lamberth; Sune Justesen; Christina Sylvester-Hvid; Esben G Schmidt; Mogens Claesson; Soren Buus; Anette Stryhn
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240

10.  NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence.

Authors:  Morten Nielsen; Claus Lundegaard; Thomas Blicher; Kasper Lamberth; Mikkel Harndahl; Sune Justesen; Gustav Røder; Bjoern Peters; Alessandro Sette; Ole Lund; Søren Buus
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

View more
  12 in total

1.  Identification of cross-reacting T-cell epitopes in structural and non-structural proteins of swine and pandemic H1N1 influenza A virus strains in pigs.

Authors:  Massimiliano Baratelli; Lasse Eggers Pedersen; Ramona Trebbien; Lars Erik Larsen; Gregers Jungersen; Esther Blanco; Jens Nielsen; Maria Montoya
Journal:  J Gen Virol       Date:  2017-05-30       Impact factor: 3.891

2.  Development and validation of an epitope prediction tool for swine (PigMatrix) based on the pocket profile method.

Authors:  Andres H Gutiérrez; William D Martin; Chris Bailey-Kellogg; Frances Terry; Leonard Moise; Anne S De Groot
Journal:  BMC Bioinformatics       Date:  2015-09-15       Impact factor: 3.169

3.  In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model.

Authors:  Andres H Gutiérrez; Crystal Loving; Leonard Moise; Frances E Terry; Susan L Brockmeier; Holly R Hughes; William D Martin; Anne S De Groot
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

4.  Specificity Characterization of SLA Class I Molecules Binding to Swine-Origin Viral Cytotoxic T Lymphocyte Epitope Peptides in Vitro.

Authors:  Caixia Gao; Xiwen He; Jinqiang Quan; Qian Jiang; Huan Lin; Hongyan Chen; Liandong Qu
Journal:  Front Microbiol       Date:  2017-12-18       Impact factor: 5.640

Review 5.  Harnessing Local Immunity for an Effective Universal Swine Influenza Vaccine.

Authors:  Elma Tchilian; Barbara Holzer
Journal:  Viruses       Date:  2017-05-05       Impact factor: 5.048

Review 6.  T and B Cell Immune Responses to Influenza Viruses in Pigs.

Authors:  Barbara Holzer; Veronica Martini; Matthew Edmans; Elma Tchilian
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

7.  Substantial Antigenic Drift in the Hemagglutinin Protein of Swine Influenza A Viruses.

Authors:  Pia Ryt-Hansen; Anders Gorm Pedersen; Inge Larsen; Charlotte Sonne Kristensen; Jesper Schak Krog; Silke Wacheck; Lars Erik Larsen
Journal:  Viruses       Date:  2020-02-23       Impact factor: 5.048

8.  Establishing the pig as a large animal model for vaccine development against human cancer.

Authors:  Nana H Overgaard; Thomas M Frøsig; Simon Welner; Michael Rasmussen; Mette Ilsøe; Maria R Sørensen; Mads H Andersen; Søren Buus; Gregers Jungersen
Journal:  Front Genet       Date:  2015-09-15       Impact factor: 4.599

9.  T-cell epitope content comparison (EpiCC) of swine H1 influenza A virus hemagglutinin.

Authors:  Andres H Gutiérrez; Vicki J Rapp-Gabrielson; Frances E Terry; Crystal L Loving; Leonard Moise; William D Martin; Anne S De Groot
Journal:  Influenza Other Respir Viruses       Date:  2017-11       Impact factor: 4.380

10.  Induction of influenza-specific local CD8 T-cells in the respiratory tract after aerosol delivery of vaccine antigen or virus in the Babraham inbred pig.

Authors:  Katie Tungatt; Garry Dolton; Sophie B Morgan; Meriem Attaf; Anna Fuller; Thomas Whalley; Johanneke D Hemmink; Emily Porter; Barbara Szomolay; Maria Montoya; John A Hammond; John J Miles; David K Cole; Alain Townsend; Mick Bailey; Pierre J Rizkallah; Bryan Charleston; Elma Tchilian; Andrew K Sewell
Journal:  PLoS Pathog       Date:  2018-05-17       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.